

Antioxidant/Oxidant Status and Cardiac Function in Bradykinin B₁- and B₂-Receptor Null Mice

S. DELEMASURE¹, N. BLAES⁴, C. RICHARD^{2,3}, R. COUTURE⁵, M. BADER⁶,
P. DUTARTRE^{1,2}, J.-P. GIROLAMI⁴, J.-L. CONNAT^{1,2}, L. ROCHETTE^{1,2}

¹COHIRO Biotechnology, Faculty of Medicine, Dijon, France, ²Laboratory of Cardio-Metabolic Pathophysiology and Pharmacology (LPPCM), INSERM, U866, Université de Bourgogne, Dijon, France, ³Department of Cardiology, University Hospital, Dijon, France, ⁴Institute of Metabolic and Cardiovascular Diseases (I2MC), INSERM, U1048, Université Paul Sabatier, Toulouse, France, ⁵Department of Physiology, Faculty of Medicine, Université de Montréal, Montréal, Qc, Canada, ⁶Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

Received December 13, 2012

Accepted June 17, 2013

On-line September 10, 2013

Summary

Kinin-vasoactive peptides activate two G-protein-coupled receptors (R), B₁R (inducible) and B₂R (constitutive). Their complex role in cardiovascular diseases could be related to differential actions on oxidative stress. This study investigated impacts of B₁R or B₂R gene deletion in mice on the cardiac function and plasma antioxidant and oxidant status. Echocardiography-Doppler was performed in B₁R (B₁R^{-/-}) and B₂R (B₂R^{-/-}) deficient and wild type (WT) adult male mice. No functional alteration was observed in B₂R^{-/-} hearts. B₁R^{-/-} mice had significantly lowered fractional shortening and increased isovolumetric contraction time. The diastolic E and A waves velocity ratio was similar in all mice groups. Thus B₁R^{-/-} mice provide a model of moderate systolic dysfunction, whereas B₂R^{-/-} mice displayed a normal cardiac phenotype. Plasma antioxidant capacity (ORAC) was significantly decreased in both B₁R^{-/-} and B₂R^{-/-} mice whereas the vitamin C levels were decreased in B₂R^{-/-} mice only. Plasma ascorbyl free radical was significantly higher in B₁R^{-/-} compared to WT and B₂R^{-/-} mice. Therefore, the oxidative stress index, ascorbyl free radical to vitamin C ratio, was increased in both B₁R^{-/-} and B₂R^{-/-} mice. Hence, B₁R and B₂R deficiency are associated with increased oxidative stress, but there is a differential imbalance between free radical production and antioxidant defense. The interrelationship between the differential B₁R and B₂R roles in oxidative stress and cardiovascular diseases remain to be investigated.

Key words

Doppler • Echocardiography • Kinin receptor • Knockout • Oxidative stress

Corresponding author

S. Delemasure, COHIRO Biotechnology, 7 Bvd Jeanne-d'Arc, Faculty of Medicine, 21000 Dijon, France. Fax: +33(0) 380393273. E-mail: sdelemasure@cohiro.fr

Introduction

Kinins are vasoactive peptides that play important roles in cardiovascular homeostasis and pathology (Regoli *et al.* 2012). They cause vasodilation, vascular permeability, and also inflammation. Kinin peptides, namely bradykinin (BK) and Lys-BK, are generated by cleavage of kininogens by plasma or tissue kallikreins. They are rapidly metabolized by kininase I and angiotensin 1-converting enzyme (Bhoola *et al.* 1992). Kinins and their C-terminal metabolites (des-Arg⁹-BK and Lys-des-Arg⁹-BK) activate G protein-coupled receptors (R), B₂R and B₁R, respectively (Regoli *et al.* 2001, Leeb-Lundberg *et al.* 2005). B₂R is constitutively expressed on endothelial cells and leads to prostacyclin and nitric oxide release through endothelial nitric oxide synthase. Kinins also induce a direct negative chronotropic effect mediated by the B₂R (Ribuot *et al.* 1993). B₁R is weakly expressed under physiological

conditions but plays a fundamental role in the cardiac function (Lauton-Santos *et al.* 2007). This receptor is strongly up-regulated by pro-inflammatory cytokines and oxygen free radicals (Couture and Girolami 2004). Oxidative stress, defined as imbalance between free radicals production and antioxidant defenses, is of great importance in the function of the kallikrein-kinin system (Dias *et al.* 2010, Kayashima *et al.* 2012). The main objective of this study was to investigate the impact of B₁R or B₂R deletion in mice on left ventricular (LV) function and plasma oxidative stress markers in physiological conditions.

Materials and Methods

Transgenic animals

B₁R^{-/-} mice (n=9) on a 129/SvJxC57/J6 background (Pesquero *et al.* 2000) were obtained from Dr. Michael Bader's Laboratory (Max-Delbrück Center for Molecular Medicine, Berlin-Buch, Germany) and backcrossed 10 times to C57BL/6J as previously reported (Mori *et al.* 2008). B₂R^{-/-} mice (n=9) on a C57BL/6J background were used (Blaes *et al.* 2012). Age-matched six-month-old male C57BL/6J wild type mice (WT, n=10) (Jackson Laboratories, Bar Harbor, Me) were used as control animals. The experimental study was approved by the local ethics committee and the investigators complied with authorization 21CAE057 from the French government, which agrees with the Directive 2010/63/EU of the European Parliament.

Echocardiographic analysis

Transthoracic micro-echocardiography was carried out as previously described (Delemeasure *et al.* 2012) using a Vevo 770[®] (Visualsonics; Toronto, Canada) equipped with a 30-MHz high-frequency linear transducer. Briefly, cardiac parameters were measured in anesthetized mice (with isoflurane) in parasternal short and long axis views, and then the values were averaged. Heart rate was measured from the cardiac cycles using three consecutive beats. Left ventricular internal diameters and LV wall thickness determined by the inter-ventricular septum, posterior wall and anterior wall were measured at end diastole and systole. Systolic function was evaluated by the fractional shortening. LV mass was calculated.

Doppler analysis

Pulsed wave Doppler of the mitral valve was

recorded from the apical four-chamber view in order to assess the diastolic function. Mitral Doppler flow spectra showed a higher early ventricular filling wave (E) and a lower late filling wave caused by atrial contraction (A). We measured the E and A wave velocities ratio (E/A), the isovolumetric relaxation time defined as the time interval between end of aortic outflow and onset of the mitral inflow, the isovolumetric contraction time defined as the time interval between end of mitral inflow and onset of the aortic outflow and informing on the dynamics of LV contraction.

Measurement of peroxy radical scavenging activity in plasma

The antioxidant scavenging activity in plasma was evaluated by Oxygen Radical Absorbance Capacity (ORAC) miniaturized assay adapted from Cao *et al.* (1993). Fluorescence decay of allophycocyanin (APC, Sigma) due to a peroxy radical generator (AAPH, 2,2-azobis(2-amidinopropane)-4-hydrochloride, Sigma) was measured over time using a Victor3V fluorimeter (PerkinElmer), with excitation and emission filters P620/8 and D665, respectively. Trolox (6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, Sigma), a soluble vitamin E analog, was used as antioxidant reference. ORAC was calculated using the net area under the decay curve and was expressed as $\mu\text{mol/l}$ of trolox equivalent (TE). For each sample, the plasma antioxidant capacity was measured in quadruplicate.

Measurement of plasma vitamin C

After mixing the plasma with metaphosphoric acid (5%), the concentrations of ascorbate and dehydroascorbic acid (total vitamin C) were measured by high performance liquid chromatography equipped with fluorescence detection (exc. = 360 nm; em. = 440 nm) (Tessier *et al.* 1996).

Detection of ascorbyl free radical in plasma and estimation of oxidative stress

Ascorbyl free radical was detected by Electron Spin Resonance (ESR) spectroscopy as previously reported (Vergely *et al.* 1998). Plasma was analyzed into a quartz capillary tube using a Bruker EMX X-band spectrometer. The formation of ascorbyl free radical was evaluated by the height of the signal and expressed in arbitrary units (AU). The plasma oxidative stress was estimated by the ascorbyl free radical to vitamin C ratio.

A.

	WT	B ₁ R ^{-/-}	B ₂ R ^{-/-}
Body weight (g)	29.9 ± 0.7	25.1 ± 0.3 *	28.4 ± 0.4
Heart rate (beats/min)	433 ± 9	441 ± 8	415 ± 6
LV anterior wall; diastole (mm)	0.77 ± 0.03	0.72 ± 0.01	0.71 ± 0.01
Inter ventricular septal wall; diastole (mm)	0.77 ± 0.03	0.72 ± 0.01	0.72 ± 0.02
LV internal diameter; diastole (mm)	4.44 ± 0.05	4.55 ± 0.05	4.45 ± 0.04
LV posterior wall; diastole (LVPW, mm)	0.77 ± 0.01	0.72 ± 0.01	0.77 ± 0.02
LV anterior wall; systole (mm)	1.01 ± 0.04	0.91 ± 0.02	0.91 ± 0.02
Inter ventricular septal wall; systole (mm)	1.02 ± 0.05	0.91 ± 0.03	0.91 ± 0.03
LV internal diameter; systole (mm)	3.29 ± 0.09	3.62 ± 0.07	3.34 ± 0.06
LV posterior wall; systole (mm)	1.07 ± 0.03	0.96 ± 0.02	1.03 ± 0.02
LV mass (mg)	132 ± 3	127 ± 2	127 ± 5
LV mass / body weight	4.4 ± 0.1	5.0 ± 0.1 *	4.5 ± 0.2

C.

	WT	B ₁ R ^{-/-}	B ₂ R ^{-/-}
E- and A-waves velocities ratio	1.4 ± 0.1	1.5 ± 0.1	1.6 ± 0.1
Isovolumetric relaxation time (ms)	18 ± 1	18 ± 1	18 ± 1
Ejection time (ms)	46 ± 3	46 ± 2	50 ± 2
Isovolumetric contraction time (ms)	21 ± 1	26 ± 2 *	20 ± 2

B.




Fig. 1. Echocardiographic analysis of wild-type (WT) and B₁R or B₂R knockout mice (B₁R^{-/-}, B₂R^{-/-}). **A.** Measures concerning body weight, heart rate and left ventricle (LV). * $P < 0.05$ versus WT. **B.** Analysis of fractional shortening in WT, B₁R or B₂R knockout mice. * $P < 0.05$ versus WT. **C.** Doppler transmitral inflow in WT, B₁R^{-/-} and B₂R^{-/-} mice. * $P < 0.05$ versus WT.

Statistical analysis

Data are expressed as mean ± SE. Differences between groups were evaluated by one-way ANOVA followed by pairwise comparisons by Student-Newman-Keuls test using SigmaPlot 11.0 (Systat software; San Jose, CA). A value of $P < 0.05$ was considered statistically significant.

Results

Echocardiographic measurements of LV

The body weights were similar for B₂R^{-/-} and WT mice but significantly lower for B₁R^{-/-} mice (minus 13 %, $P < 0.05$) (Fig. 1A). LV weights, measured by echocardiography, were similar for the three groups (mean of 128 mg). The heart to body weight ratio was thus significantly higher in B₁R^{-/-} (5.0±0.1) compared to B₂R^{-/-} (4.5±0.2) and WT (4.4±0.1) mice. The heart rates were stable and did not significantly differ between B₁R^{-/-}, B₂R^{-/-} and WT mice, with a mean of 430 beats/min under anesthetized conditions (Fig. 1A). LV wall thickness measurements were similar for the knockout and WT mice. An upward trend, however not statistically significant, was noted for left ventricular internal diameter in B₁R^{-/-} mice compared to B₂R^{-/-} and WT mice. Consequently, B₁R^{-/-} mice had a significant decline in fractional shortening compared to B₂R^{-/-} and WT (-18 %, $P < 0.05$) mice (Fig. 1B).

Doppler measurements of transmitral LV inflow

B₁R^{-/-} and B₂R^{-/-} mice had E and A wave velocities ratio and isovolumetric relaxation time similar to WT mice (Fig. 1C). The mitral ejection time was unchanged. An increased isovolumetric contraction time was observed in B₁R^{-/-} compared to B₂R^{-/-} and WT mice (+27 %, $P < 0.05$).

Plasma Oxygen Radical Absorbance Capacity

The antioxidant status evaluated by ORAC was significantly lower in both B₁R^{-/-} mice (1492±47 μmol/l TE) and B₂R^{-/-} mice (1781±55 μmol/l TE) compared to WT mice (2322±84 μmol/l TE) ($P < 0.05$) (Fig. 2A). B₁R^{-/-} and B₂R^{-/-} ORAC did not significantly differ.

Plasma vitamin C and ascorbyl free radical

Plasma total vitamin C levels did not significantly differ between B₁R^{-/-} and WT mice (51±4 versus 60±4 μmol/l) (Fig. 2B). In contrast, it was significantly lower in B₂R^{-/-} mice (36±5 μmol/l, $P < 0.05$) compared to WT mice. The height of the signal intensity of the characteristic spectra of plasma ascorbyl free radical was similar in B₂R^{-/-} and WT mice. In contrast, B₁R^{-/-} mice exhibited a markedly higher signal intensity in comparison with WT or B₂R^{-/-} mice (+41 %, $P < 0.05$; Fig. 2C and 2D). The plasma oxidative stress, as evaluated by the ascorbyl free radical to vitamin C ratio, was increased in B₁R^{-/-} and B₂R^{-/-} mice as compared to WT mice ($P < 0.05$). The difference between B₁R^{-/-} and B₂R^{-/-} mice did not reach statistical significance (Fig. 2E).




Fig. 2. Plasma antioxidant status in WT and B₁R^{-/-}, B₂R^{-/-} mice. **A.** Determination using ORAC (Oxygen Radical Absorbance Capacity) measurements. **B.** Total plasma vitamin C quantified using HPLC. **P*<0.05 versus WT. **C.** Characteristic doublet of ascorbyl free radical ESR signal. ESR spectra were recorded with Bruker EMX X-band spectrometer using a quartz capillary tube at room temperature. **D.** Quantification of ascorbyl free radical determined by the measure of the ESR signal height. **P*<0.05 versus WT. **E.** Plasma oxidative stress evaluated by the ascorbyl free radical to vitamin C ratio in WT and B₁R^{-/-}, B₂R^{-/-} mice. **P*<0.05 versus WT.

Discussion

Antioxidant/oxidant status

Although we do not bring indications on myocardial oxidative stress markers, this study extends the knowledge of the phenotypes of B₁R and B₂R null mice. A decrease in plasma antioxidant scavenging activity (ORAC) was observed in both deficient strains. However, other plasma oxidative stress markers were differentially altered. Plasma total vitamin C concentration was decreased in B₂R^{-/-} mice but not in B₁R^{-/-} mice, suggesting that B₂R deficiency impacted synthesis and/or recycling of ascorbate. Total vitamin C (L-ascorbic acid and its oxidized form, dehydroascorbic acid) acts as essential water-soluble antioxidant in plasma (Farbstein *et al.* 2010). In humans, vitamin C must be provided in the diet while mice can synthesize ascorbate from glucose in the liver by the L-gulonolactone oxidase. Reduction of total vitamin C may result from increased renal excretion or to decreased liver synthesis. At physiological pH, L-ascorbic acid primarily exists as

ascorbate anion which, in presence of oxygen free radicals, results in ascorbyl free radical, stable enough to be detected by ESR spectroscopy in plasma (Vergely *et al.* 1998). The plasma ascorbyl free radical content was only increased in B₁R^{-/-}. Nevertheless, the ascorbyl free radical to vitamin C ratio, index of oxidative stress (Courderot-Masuyer *et al.* 2000), was markedly increased in both B₁R^{-/-} and B₂R^{-/-} mice. The alterations of the antioxidant/oxidant status in B₁R^{-/-} and B₂R^{-/-} mice versus WT mice indicate that both kinin receptors control the oxidative balance under physiological conditions, although by different routes. In pathology, the B₁R and B₂R roles are distinct (Kayashima *et al.* 2012). B₁R is involved in insulin resistance and in early diabetes by increasing oxidative stress and pro-inflammatory mediators and later vascular alterations (Dias *et al.* 2012, Pouliot *et al.* 2012) while B₂R is involved in cardiovascular protection (Couture and Girolami 2004) and is necessary for cardioprotective effects provided by angiotensin-converting enzyme inhibitors, even if B₁R can contribute to protective effects (Duka *et al.* 2008).

Left ventricular systolic and diastolic functions

Previous evaluations of *in vivo* cardiac function in kinin receptor deficient mice brought somehow variable results under physiological conditions. No echocardiographic alteration was reported for 10-week B₂R^{-/-} male mice (Yang *et al.* 2001, Duka *et al.* 2008) or 5-month female (Trabold *et al.* 2002) or in male mice of several B₁R^{-/-} strains (Duka *et al.* 2008, Westermann *et al.* 2009, Wende *et al.* 2010). In contrast, diastolic LVID was increased in female 12-week-old B₁R^{-/-} mice (Xu *et al.* 2009), and 2-month-old B₂R^{-/-} mice showed higher LV mass and LVID at end-systole together with lower ejection fraction (Osorio *et al.* 2008). Older B₂R^{-/-} mice (12-month-old) had moderately altered LV contractility and diastolic function (Madeddu *et al.* 1997). Alterations were more severe in the 129/J strain, showing the impact of interaction of B₂R signaling with other genetic determinant (two renin gene copy number) (Maestri *et al.* 2003). Collectively, described cardiac alterations of B₁R^{-/-} and B₂R^{-/-} mice remain moderate. Discrepancies may result from variation in the physiological conditions, i.e. gender, age or genetic background, isolated hearts or anesthetized animals or from differences in the methods to evaluate cardiac function. In this present study, a normal cardiac phenotype was observed in B₂R^{-/-} mice. Although not significantly, most ventricular wall measures (posterior or anterior wall, in systole or diastole) were slightly lower for B₁R^{-/-} hearts. These results argue for conditions of mild volume overload causing cavity dilation and thinning of the ventricular wall (Ram *et al.* 2011). Some measurements obtained from WT mice appeared lower than previously published values (Ram *et al.* 2011); this might be due to anesthesia-induced minor cardiac depression (also suggested by heart beats <500/min). However, in our study anesthesia conditions were comparable for the three mice strains. We showed a decrease of fractional shortening in B₁R^{-/-} 6-month-old male mice. Consistently, previous *ex vivo* data showed a lower systolic function without hypertrophy in isolated hearts of 16-week-old male mice (Lauton-Santos *et al.* 2007). In B₁R or B₂R deficient mouse hearts, the other kinin receptor was found up-regulated in physiological state (Duka *et al.* 2008). Although moderate, the present systolic dysfunction in

the B₁R^{-/-} hearts may be the consequence of B₂R up-regulation and subsequent excessive negative chronotropic effect (Ribuot *et al.* 1993) but may also argued for a role of B₁R in the control of basal cardiac function. Our study is the first to assess the diastolic LV function by noninvasive conventional Doppler in mice lacking B₁R or B₂R. Transmitral pressure gradient and LV filling pressure were estimated as generally performed in patients. There was no difference between B₁R^{-/-}, B₂R^{-/-} and WT mice with regard to the diastolic function, as evaluated by the early to late diastolic filling ratio and the time between aortic valve closure and mitral valve opening. A prolonged time between mitral valve closure and aortic valve opening was observed in B₁R^{-/-} mice, which confirms an impaired LV contraction.

Conclusion

Deficiency in either kinin receptor altered the plasma oxidant/antioxidant balance, however with specific patterns. In addition, B₁R deficiency induced a moderate systolic dysfunction consistent with a role of B₁R in the control of the basal cardiac function. Consequences of such differential roles of B₁R and B₂R remain to be investigated in oxidative pathological conditions and metabolic cardiovascular diseases.

Conflict of Interest

There is no conflict of interest.

Acknowledgements

Vevo770[®] echocardiograph was funded by European Community Funds (FEDER), Burgundy Regional Council and French Ministry for Research (MESR). Victor Plate reader was funded by French Ministry for Higher Education & Research (MESR). Mice were bred at the Animal Unit of INSERM Ranguel (Genotoul Anexplo Plateforme, Toulouse) then housed in the Zootechnic Center of Université de Bourgogne (Dijon). This work was supported by grants from University Paul Sabatier Toulouse, INSERM, and from the INSERM/FRSQ scientific exchange program (R. Couture/J.-P. Girolami).

References

- BHOOLA KD, FIGUEROA CD, WORTHY K: Bioregulation of kinins: kallikreins, kininogens, and kininases. *Pharmacol Rev* 44: 1-80, 1992.

- BLAES N, PECHER C, MEHRENBERGER M, CELLIER E, PRADDAUDE F, CHEVALLIER J, TACK I, COUTURE R, GIROLAMI JP: Bradykinin inhibits high glucose- and growth factor-induced collagen synthesis in mesangial cells through the B2-kinin receptor. *Am J Physiol Renal Physiol* **303**: F293-F303, 2012.
- CAO G, ALESSIO HM, CUTLER RG: Oxygen-radical absorbance capacity assay for antioxydants. *Free Radic Biol Med* **14**: 303-311, 1993.
- COURDEROT-MASUYER C, LAHET JJ, VERGES B, BRUN J-M, ROCHETTE L: Ascorbyl free radical release in diabetic patients. *Cell Mol Biol* **46**: 1397-1401, 2000.
- COUTURE R, GIROLAMI J-P: Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus. *Eur J Pharmacol* **500**: 467-485, 2004.
- DELEMASURE S, RICHARD C, GAMBERT S, GUILLAND J-C, VERGELY C, DUTARTRE P, ROCHETTE L, CONNAT J-L: Impact of high-fat diet on antioxidant status, vascular wall thickening and cardiac function in adult female LDLR^{-/-} mice. *World J Cardiovasc Dis* **2**: 184-192, 2012.
- DIAS JP, COUTURE R: Suppression of vascular inflammation by kinin B₁ receptor antagonism in a rat model of insulin resistance. *J Cardiovasc Pharmacol* **60**: 61-69, 2012.
- DUKA A, KINTSURASHVILI E, DUKA I, ONA D, HOPKINS TA, BADER M, GAVRAS I, GAVRAS H: Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors. *Hypertension* **51**: 1352-1357, 2008.
- FARBSTEIN D, KOZAK-BLICKSTEIN A, LEVY AP: Antioxidant vitamins and their use in preventing cardiovascular disease. *Molecules* **15**: 8098-8110, 2010.
- KAYASHIMA Y, SMITHIES O, KAKOKI M: The kallikrein-kinin system and oxidative stress. *Curr Opin Nephrol Hypertens* **21**: 92-96, 2012.
- LAUTON-SANTOS S, GUATIMOSIM S, CASTRO CH, OLIVEIRA FA, ALMEIDA AP, DIAS-PEIXOTO MF, GOMES MA, PESSOA P, PESQUERO JL, PESQUERO JB, BADER M, CRUZ JS: Kinin B₁ receptor participates in the control of cardiac function in mice. *Life Sci* **81**: 814-822, 2007.
- LEEB-LUNDBERG LM, MARCEAU F, MULLER-ESTERL W, PETTIBONE DJ, ZURAW BL: Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. *Pharmacol Rev* **57**: 27-77, 2005.
- MADEDDU P, VARONI MV, PALOMBA D, EMANUELI C, DEMONTIS MP, GLORIOSO N, DESSI-FULGHERI P, SARZANI R, ANANIA V: Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. *Circulation* **96**: 3570-3578, 1997.
- MAESTRI R, MILIA AF, SALIS MB, GRAIANI G, LAGRASTA C, MONICA M, CORRADI D, EMANUELI C, MADEDDU P: Cardiac hypertrophy and microvascular deficit in kinin B2 receptor knockout mice. *Hypertension* **41**: 1151-1155, 2003.
- OSORIO JC, CHEEMA FH, MARTENS TP, MAHMUT N, KINNEAR C, GONZALES AM, BONNEY W, HOMMA S, LIAO JK, MITAL S: Simvastatin reverses cardiac hypertrophy caused by disruption of the bradykinin 2 receptor. *Can J Physiol Pharmacol* **86**: 633-642, 2008.
- PESQUERO JB, ARAUJO RC, HEPPENSTALL PA, STUCKI CL, SILVA JA JR, WALTHER T, OLIVEIRA SM, PESQUERO JL, PAIVA AC, CALIXTO JB, LEWIN GR, BADER M: Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. *Proc Natl Acad Sci USA* **97**: 8140-8145, 2000.
- POULIOT M, TALBOT S, SENECAI J, DOTIGNY F, VAUCHER E, COUTURE R: Ocular application of the kinin B₁ receptor antagonist LF22-0542 inhibits retinal inflammation and oxidative stress in streptozotocin-diabetic rats. *PLoS One* **7**: e33864, 2012.
- RAM R, MICLELSEN DM, THEODOROPOULOS C, BLAXALL BC: New approaches in small animal echocardiography: imaging the sounds of silence. *Am J Physiol Heart Circ Physiol* **301**: H1765-H1780, 2011.
- REGOLI D, PLANTE GE, GOBEIL F JR: Impact of kinins in the treatment of cardiovascular diseases. *Pharmacol Ther* **135**: 94-111, 2012.
- REGOLI D, RIZZI A, PERRON SI, GOBEIL F JR: Classification of kinin receptors. *Biol Chem* **382**: 31-35, 2001.
- RIBUOT C, GODIN D, COUTURE R, REGOLI D, NADEAU R: In vivo B₂-receptor-mediated negative chronotropic effect of bradykinin in canine sinus node. *Am J Physiol* **265**: H876-H879, 1993.

-
- TESSIER F, BIRLOUEZ-ARAGON I, TJANI C, GUILLAND J-C: Validation of a micromethod for determining oxidized and reduced vitamin C in plasma by HPLC-fluorescence. *Int J Vitam Nutr Res* **66**: 166-170, 1996.
- TRABOLD F, PONS S, HAGEGE AA, BLOCH-FAURE M, ALHENC-GELAS F, GIUDICELLI F, RICHER-GIUDICELLI C, MENETON P: Cardiovascular phenotypes of kinin B2 receptor- and tissue kallikrein-deficient mice. *Hypertension* **40**: 90-95, 2002.
- VERGELY C, MAUPOIL V, BENDERITTER M, ROCHETTE L: Influence of the severity of myocardial ischemia on the intensity of ascorbyl free radical release and on postischemic recovery during reperfusion. *Free Radic Biol Med* **24**: 470-479, 1998.
- WENDE AR, SOTO J, OLSEN CD, PIRES KM, SCHELL JC, LARRIEU-LAHARGUE F, LITWIN SE, KAKOKI M, TAKAHASHI N, SMITHIES O, ABEL ED: Loss of bradykinin signaling does not accelerate the development of cardiac dysfunction in type 1 diabetic akita mice. *Endocrinology* **151**: 3536-3342, 2010.
- WESTERMANN D, WALTHER T, SAVVATIS K, ESCHER F, SOBIREY M, RIAD A, BADER M, SCHULTHEISS HP, TSCHOPE C: Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. *Diabetes* **58**: 1373-1381, 2009.
- XU J, CARRETERO OA, SHESELY EG, RHALEB NE, YANG JJ, BADER M, YANG XP: The kinin B₁ receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice. *Exp Physiol* **94**: 322-329, 2009.
- YANG XP, LIU YH, MEHTA D, CAVASIN MA, SHESELY EG, XU J, LIU F, CARRETERO OA: Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice. *Circ Res* **88**: 1072-1079, 2001.
-